These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 12853521)
1. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Utz JP; Limper AH; Kalra S; Specks U; Scott JP; Vuk-Pavlovic Z; Schroeder DR Chest; 2003 Jul; 124(1):177-85. PubMed ID: 12853521 [TBL] [Abstract][Full Text] [Related]
2. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Rouhani FN; Meitin CA; Kaler M; Miskinis-Hilligoss D; Stylianou M; Levine SJ Respir Med; 2005 Sep; 99(9):1175-82. PubMed ID: 16085220 [TBL] [Abstract][Full Text] [Related]
4. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions]. Paul C; Solignac M Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165 [No Abstract] [Full Text] [Related]
5. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Bozkurt B; Torre-Amione G; Warren MS; Whitmore J; Soran OZ; Feldman AM; Mann DL Circulation; 2001 Feb; 103(8):1044-7. PubMed ID: 11222463 [TBL] [Abstract][Full Text] [Related]
6. [TNFα blocking agents and sarcoidosis: an update]. Toussirot E; Pertuiset E Rev Med Interne; 2010 Dec; 31(12):828-37. PubMed ID: 20510487 [TBL] [Abstract][Full Text] [Related]
7. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. de Vlam K; Lories RJ Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275 [TBL] [Abstract][Full Text] [Related]
10. Inter-relationship between tumour necrosis factor-alpha (TNF-alpha) and TNF soluble receptors in pulmonary sarcoidosis. Armstrong L; Foley NM; Millar AB Thorax; 1999 Jun; 54(6):524-30. PubMed ID: 10335007 [TBL] [Abstract][Full Text] [Related]
11. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Goldenberg MM Clin Ther; 1999 Jan; 21(1):75-87; discussion 1-2. PubMed ID: 10090426 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Madhusudan S; Foster M; Muthuramalingam SR; Braybrooke JP; Wilner S; Kaur K; Han C; Hoare S; Balkwill F; Talbot DC; Ganesan TS; Harris AL Clin Cancer Res; 2004 Oct; 10(19):6528-34. PubMed ID: 15475440 [TBL] [Abstract][Full Text] [Related]
13. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Epstein MP; Kaplan MM Dig Dis Sci; 2004 Jan; 49(1):1-4. PubMed ID: 14992426 [TBL] [Abstract][Full Text] [Related]
15. Etanercept for psoriasis: two case reports. Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631 [TBL] [Abstract][Full Text] [Related]
16. Etanercept: an overview of its role in the treatment of psoriasis. Galindo MP; Bartlett BL; Gewirtzman A; Mendoza N; Tremaine AM; Tyring SK Expert Opin Drug Metab Toxicol; 2008 Mar; 4(3):305-10. PubMed ID: 18363545 [TBL] [Abstract][Full Text] [Related]
17. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734 [TBL] [Abstract][Full Text] [Related]
18. The medical uses and side effects of etanercept with a focus on cutaneous disease. Scheinfeld N J Drugs Dermatol; 2004; 3(6):653-9. PubMed ID: 15624748 [TBL] [Abstract][Full Text] [Related]
19. Etanercept: efficacy and safety for approved indications. Kerensky TA; Gottlieb AB; Yaniv S; Au SC Expert Opin Drug Saf; 2012 Jan; 11(1):121-39. PubMed ID: 22074366 [TBL] [Abstract][Full Text] [Related]